Compare American International Group Inc (AIG) vs Boston Scientific Corporation (BSX) Price & Performance

AIG trades at $78.78, down 1.49% on the day, with a neutral technical stance as RSI readings near 42 suggest balanced momentum. The stock shows solid fundamentals with a P/E of 14.38 and recent earnings beats, including Q2 2026 EPS of $2.00 versus $1.92 expected. Revenue stability around $26.8 billion in 2025 and a net income margin of 11.88% reflect disciplined underwriting and expense control, though investment income headwinds persist. Analyst consensus price target is $88.90, implying potential upside, supported by a 39% buy rating among coverage.

Outlook remains cautiously optimistic given earnings consistency and undervaluation relative to peers, but risks include competitive pricing pressure and macroeconomic volatility affecting insurance demand. The dividend yield of approximately 2.5% adds income appeal, yet high beta exposure may lead to amplified swings in broader market downturns, warranting monitoring of Q3 2026 results for sustained growth catalysts.

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.